This is a delivery order contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit research organization and subsidiary of Temple University. The $988,252 firm fixed price contract is for research and development services in the area of biomedical basic research, specifically preclinical efficacy and biomarker analysis to support the NCI's PREVENT Cancer Preclinical Drug Development Program....
This federal contract award was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to The Institute for Cancer Research, a non-profit organization and subsidiary of Temple University. The $1,570,991.00 task order is part of the PREVENT Preclinical Drug Development Program, which focuses on preclinical efficacy and intermediate endpoint biomarker testing for cancer prevention drug candidates. The task order is for a project titled...
This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI) to IIT Research Institute (IITRI), a non-profit preclinical contract research organization (CRO). The contract is for $532,562.26 to evaluate a breast cancer prevention agent under the PREVENT Cancer Preclinical Drug Development Program, a $149.995 million NCI Indefinite Delivery Vehicle (IDV) that IITRI holds. IITRI has extensive experience providing preclinical drug development services to federal agencies...
The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January...
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $23,349,236 contract is for the provision of preclinical in vitro and in vivo screening assays to support the development of cancer preventive agents. IITRI, which has extensive experience supporting the preclinical development of various therapeutics for federal...
This is a delivery order issued against the Preclinical Agent Development Assays 2012-2016 contract vehicle by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract was awarded to the IIT Research Institute (IITRI), a non-profit contract research organization, to conduct other functions related to preclinical in vitro and in vivo agent development assays, including an orientation meeting. The total ceiling value of this...
This is a delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $1,725 firm fixed price order is for a contract orientation meeting and is part of a larger $146.3 million IDIQ contract between IITRI and the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical models of infectious diseases. IITRI has...
This federal contract award, valued at $33,483,214.15, was issued by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for preclinical pharmacology and toxicology studies to support the development of small molecule, biologic, and RNA therapeutic candidates across various disease areas. IITRI has extensive experience providing these services to...
The National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services, awarded a $1,038,958 Firm Fixed Price Delivery Order to The Institute For Cancer Research Division of Temple University-Of The Commonwealth System Of Higher Education. The Delivery Order was issued against PREVENT Preclinical Drug Development Program Indefinite Delivery Indefinite Quantity Master Contract to fund research on COLORECTAL CANCER PREVENTION BY UROLITHIN...
This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...
This is a $547,860 delivery order contract awarded by the National Cancer Institute (NCI) of the Department of Health and Human Services (HHS) to The Institute for Cancer Research, a non-profit research organization. The contract is part of the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle, which supports the PREVENT Cancer Preclinical Drug Development Program. Under this 5-year IDIQ, The Institute for Cancer Research provides preclinical efficacy testing and biomarker analysis services for evaluating candidate cancer preventive therapies. The contract does not have a set-aside designation. The Institute for Cancer Research has previously served as a subcontractor on federal grants and contracts, contributing specialized cancer research capabilities. This particular delivery order is focused on continued evaluation of chemopreventive and immunopreventive regimens.